Lanceta L, Lypova N, O’Neill C, et al. Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq. Breast Cancer Research and Treatment. 2021; 186(3):677-86.
 Zhou Y, Yamamoto Y, Takeshita F, et al. Delivery of miR-424-5p via Extracellular vesicles promotes the apoptosis of MDA-MB-231 TNBC cells in the tumor microenvironment. International Journal of Molecular Sciences. 2021; 22(2):844.
 Bai X, Ni J, Beretov J, et al. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel? Cancer Letters. 2021; 497:100-11.
 El‐Sayed ESR. Discovery of the Anticancer Drug Vinblastine from the Endophytic Alternaria alternata and Yield Improvement by Gamma Irradiation Mutagenesis. Journal of Applied Microbiology. 2021.
 Aggarwal S, Verma SS, Aggarwal S, et al. Drug repurposing for breast cancer therapy: Old weapon for new battle. 2021: Elsevier.
 Aramjoo H, Zadeh HE, Hemmati M. Investigation of Protective Effects of Quercetin on Oxidative Stress Induced by Vinblastine in Bone Marrow of Rats. Pharmaceutical Sciences. 2020.
 Zhou H, Liu L, Ma X, et al. RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage. Molecular and Cellular Biochemistry. 2021; 476(2):1233-43.
 Baksi R, Rana R, Nivsarkar M. Chemopreventive potential of plant-derived epigenetic inhibitors silibinin and quercetin: an involvement of apoptotic signaling cascade modulation. Future Journal of Pharmaceutical Sciences. 2021; 7(1):1-13.
 Delmas D, Xiao J, Vejux A, et al. Silymarin and cancer: A dual strategy in both in chemoprevention and chemosensitivity. Molecules. 2020; 25(9):2009.
 Mao J, Yang H, Cui T, et al. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. European journal of pharmacology. 2018; 832:39-49.
 Tiwari P, Mishra K. Silibinin in cancer therapy: A promising prospect. Cancer Res Front. 2015; 1(3):303-18.
 Sak K. Chemotherapy and dietary phytochemical agents. Chemotherapy research and practice. 2012; 2012.
 Chavoshi H, Vahedian V, Saghaei S, et al. Adjuvant therapy with silibinin improves the efficacy of paclitaxel and cisplatin in MCF-7 breast cancer cells. Asian Pacific journal of cancer prevention: APJCP. 2017; 18(8):2243.
 Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in enzyme regulation. 1984; 22:27-55.
 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods. 2001; 25(4):402-8.
 Brandl MB, Pasquier E, Li F, et al. Computational analysis of image-based drug profiling predicts synergistic drug combinations: Applications in triple-negative breast cancer. Molecular oncology. 2014; 8(8):1548-60.
 Li J, Chen S, Chen C, et al. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy. Oncotarget. 2017; 8(11):18399.
 Choudhari AS, Mandave PC, Deshpande M, et al. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Frontiers in pharmacology. 2020; 10:1614.
 Gigant B, Wang C, Ravelli RB, et al. Structural basis for the regulation of tubulin by vinblastine. Nature. 2005; 435(7041):519-22.
 Pfister C, Gravis G, Fléchon A, et al. Randomized phase III trial of dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: Chemotherapy toxicity and pathological responses. European Urology. 2021; 79(2):214-21.
 Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, et al. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pacific Journal of Cancer Prevention. 2013; 14(11):6595-9.
 Esmaeil Lashgarian H, Adamii V, Ghorbanzadeh V, et al. Silibinin Inhibit Cell Migration through Downregulation of RAC1 Gene Expression in Highly Metastatic Breast Cancer Cell Line. Drug Res (Stuttg). 2020.
 Tuli HS, Mittal S, Aggarwal D, et al. Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance. 2020: Elsevier.
 Tyagi AK, Agarwal C, Chan DC, et al. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncology reports. 2004; 11(2):493-9.
 Sharma A, Kaur M, Katnoria JK, et al. Polyphenols in food: Cancer prevention and apoptosis induction. Current medicinal chemistry. 2018; 25(36):4740-57.
 Lee J-W, Park S, Kim SY, et al. Curcumin hampers the antitumor effect of vinblastine via the inhibition of microtubule dynamics and mitochondrial membrane potential in HeLa cervical cancer cells. Phytomedicine. 2016; 23(7):705-13.
 Li L, Zeng J, Gao Y, et al. Targeting silibinin in the antiproliferative pathway. Expert opinion on investigational drugs. 2010; 19(2):243-55.
 D’Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell biology international. 2019; 43(6):582-92.